Back to Search Start Over

Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB.

Authors :
Nielsen MA
Juul-Madsen K
Stegmayr J
Gao C
Mehta AY
Greisen SR
Kragstrup TW
Hvid M
Vorup-Jensen T
Cummings RD
Leffler H
Deleuran BW
Source :
Frontiers in immunology [Front Immunol] 2022 Jun 24; Vol. 13, pp. 915890. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022).
Publication Year :
2022

Abstract

4-1BB is a T cell costimulatory receptor and a member of the tumor necrosis factor receptor superfamily. Here, we show that Galectin-3 (Gal-3) decreases the cellular response to its ligand (4-1BBL). Gal-3 binds to both soluble 4-1BB (s4-1BB) and membrane-bound 4-1BB (mem4-1BB), without blocking co-binding of 4-1BBL. In plasma, we detected complexes composed of 4-1BB and Gal-3 larger than 100 nm in size; these complexes were reduced in synovial fluid from rheumatoid arthritis. Both activated 4-1BB <superscript>+</superscript> T cells and 4-1BB-transfected HEK293 cells depleted these complexes from plasma, followed by increased expression of 4-1BB and Gal-3 on the cell surface. The increase was accompanied by a 4-fold decrease in TNFα production by the 4-1BB <superscript>high</superscript> Gal-3 <superscript>+</superscript> T cells, after exposure to 4-1BB/Gal-3 complexes. In RA patients, complexes containing 4-1BB/Gal-3 were dramatically reduced in both plasma and SF compared with healthy plasma. These results support that Gal-3 binds to 4-1BB without blocking the co-binding of 4-1BBL. Instead, Gal-3 leads to formation of large soluble 4-1BB/Gal-3 complexes that attach to mem4-1BB on the cell surfaces, resulting in suppression of 4-1BBL's bioactivity.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Nielsen, Juul-Madsen, Stegmayr, Gao, Mehta, Greisen, Kragstrup, Hvid, Vorup-Jensen, Cummings, Leffler and Deleuran.)

Details

Language :
English
ISSN :
1664-3224
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
35812455
Full Text :
https://doi.org/10.3389/fimmu.2022.915890